Literature DB >> 12802904

Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system.

J Baillargeon1, H Wu, M J Kelley, J Grady, L Linthicum, K Dunn.   

Abstract

The seroprevalence of hepatitis C (HCV) infection was examined among a sample of incoming inmates in the Texas Department of Criminal Justice (TDCJ) prison system. Rates were compared across demographic factors and three types of prison facilities: substance abuse felony punishment units (SAFPs), state jails and prisons. The study sample consisted of 3712 incoming inmates incarcerated for any duration, dating from 1 November 1998 to 31 May 1999. Among males, inmates entering SAFPs and state jails had comparable HCV infection rates (29.7 and 27.0%, respectively) to those entering prisons (27.3%). Among females, inmates entering prisons had a higher rate of infection (48.6%) than those entering state jails (35.1%) or SAFPs (38.3%). For both genders, blacks exhibited a lower overall infection rate than whites and Hispanics, and HCV seroprevalence increased in a stepwise fashion with age. All subgroups of TDCJ inmates, including those held in alternative correctional facilities, exhibited HCV infection rates that were comparable with previous reports of inmate populations, but dramatically higher than general community samples. Given that most inmates held in alternative facilities will return to the general community in a short period of time, understanding the HCV infection rates in these subgroups holds particular public health relevance.

Entities:  

Mesh:

Year:  2003        PMID: 12802904     DOI: 10.1016/s0033-3506(02)00009-4

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  29 in total

1.  Disease prevalence and use of health care among a national sample of black and white male state prisoners.

Authors:  David L Rosen; Wizdom P Hammond; David A Wohl; Carol E Golin
Journal:  J Health Care Poor Underserved       Date:  2012-02

2.  Drug use, hepatitis C, and service availability: perspectives of incarcerated rural women.

Authors:  Michele Staton-Tindall; J Matthew Webster; Carrie B Oser; Jennifer R Havens; Carl G Leukefeld
Journal:  Soc Work Public Health       Date:  2015

3.  The prevalence of hepatitis C virus infection in Texas: implications for future health care.

Authors:  Kanthi Yalamanchili; Sherif Saadeh; Rita Lepe; Gary L Davis
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-01

4.  From corrections to communities as an HIV priority.

Authors:  David Vlahov; Sara Putnam
Journal:  J Urban Health       Date:  2006-05       Impact factor: 3.671

5.  Prisoners favour hepatitis C testing and treatment.

Authors:  S Vallabhaneni; G E Macalino; S E Reinert; B Schwartzapfel; F A Wolf; J D Rich
Journal:  Epidemiol Infect       Date:  2006-04       Impact factor: 2.451

Review 6.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

7.  Liver cancer mortality among male prison inmates in Texas, 1992-2003.

Authors:  Amy J Harzke; Jacques G Baillargeon; Karen J Goodman; Sandi L Pruitt
Journal:  Prev Med       Date:  2009-03-13       Impact factor: 4.018

8.  Estimating HCV prevalence at the state level: a call to increase and strengthen current surveillance systems.

Authors:  Rachel Hart-Malloy; Alvaro Carrascal; A Gregory Dirienzo; Colleen Flanigan; Kristi McClamroch; Lou Smith
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

9.  Hepatitis C seroprevalence among prison inmates since 2001: still high but declining.

Authors:  Aiden K Varan; Daniel W Mercer; Matthew S Stein; Anne C Spaulding
Journal:  Public Health Rep       Date:  2014 Mar-Apr       Impact factor: 2.792

10.  HCV-related mortality among male prison inmates in Texas, 1994-2003.

Authors:  Amy J Harzke; Jacques G Baillargeon; Michael F Kelley; Pamela M Diamond; Karen J Goodman; David P Paar
Journal:  Ann Epidemiol       Date:  2009-05-13       Impact factor: 3.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.